Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Authors: Kambugu, Andrew, Kaimal, Arvind, Castelnuovo, Barbara, Kiiza, Daniel, Asienzo, Jesca, Kisembo, John, Nsubuga, John, Okwero, Max, Muyise, Rhona, Kityo, Cissy, Nasaazi, Claire, Nakiboneka, Dridah L., Mugerwa, Henry, Namusanje, Josephine, Najjuuko, Theresa, Masaba, Timothy, Serumaga, Timothy, Alinaitwe, Adolf, Arinda, Allan, Rweyora, Angela, Ategeka, Gilbert, Kangah, Mary Goretti, Lugemwa, Abbas, Kasozi, Mariam, Tukumushabe, Phionah, Akunda, Rogers, Makumbi, Shafic, Musumba, Sharif, Myalo, Sula, Ahuura, John, Namusisi, Annet Mary, Kibirige, Daniel, Kiweewa, Francis, Mirembe, Grace, Mabonga, Habert, Wandege, Joseph, Nakakeeto, Josephine, Namubiru, Sharon, Nansalire, Winfred, Siika, Abraham Mosigisi, Kwobah, Charles Meja, Mboya, Chris Sande, Mokaya, Martha Mokeira Bisieri, Karoney, Mercy Jelagat, Cheruiyot, Priscilla Chepkorir, Cherutich, Salinah, Njuguna, Simon Wachira, Kirui, Viola Cherotich, Borok, Margaret, Chidziva, Ennie, Musoro, Godfrey, Hakim, James, Bhiri, Joyline, Phiri, Misheck, Mudzingwa, Shepherd, Manyanga, Tadios, Kiragga, Agnes, Banegura, Anchilla Mary, Hoppe, Anne, Balyegisawa, Apolo, Agwang, Betty, Isaaya, Brian, Tumwine, Constantine, Odongpiny, Eva Laker A., Musaazi, Joseph, Paton, Nicholas, Senkungu, Peter, Walimbwa, Stephen, Kamara, Yvonne, Amperiize, Mathius, Allen, Elizabeth, Opondo, Charles, Mohammed, Perry, van Rein-van der Horst, Willemijn, Van Delft, Yvon, Boateng, Fafa Addo, Namara, Doreen, Kaleebu, Pontiano, Ojoo, Sylvia, Bwakura, Tapiwanashe, Katana, Milly, Venter, Francois, Phiri, Sam, Walker, Sarah, Paton, Nicholas I ^*, Siika, Abraham, Odongpiny, Eva Laker A

Source: In The Lancet HIV June 2022 9(6):e381-e393

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Authors: Paton, Nicholas I, Musaazi, Joseph, Kityo, Cissy, Walimbwa, Stephen, Hoppe, Anne, Balyegisawa, Apolo, Asienzo, Jesca, Kaimal, Arvind, Mirembe, Grace, Lugemwa, Abbas, Ategeka, Gilbert, Borok, Margaret, Mugerwa, Henry, Siika, Abraham, Odongpiny, Eva Laker A, Castelnuovo, Barbara, Kiragga, Agnes, Kambugu, Andrew, Kambugu, Andrew, Kaimal, Arvind, Castelnuovo, Barbara, Kiiza, Daniel, Asienzo, Jesca, Kisembo, John, Nsubuga, John, Okwero, Max, Muyise, Rhona, Kityo, Cissy, Nasaazi, Claire, Nakiboneka, Dridah L., Mugerwa, Henry, Namusanje, Josephine, Najjuuko, Theresa, Masaba, Timothy, Serumaga, Timothy, Alinaitwe, Adolf, Arinda, Allan, Rweyora, Angela, Ategeka, Gilbert, Kangah, Mary Goretti, Lugemwa, Abbas, Kasozi, Mariam, Tukumushabe, Phionah, Akunda, Rogers, Makumbi, Shafic, Musumba, Sharif, Myalo, Sula, Ahuura, John, Namusisi, Annet Mary, Kibirige, Daniel, Kiweewa, Francis, Mirembe, Grace, Mabonga, Habert, Wandege, Joseph, Nakakeeto, Josephine, Namubiru, Sharon, Nansalire, Winfred, Siika, Abraham Mosigisi, Kwobah, Charles Meja, Mboya, Chris Sande, Mokaya, Martha Mokeira Bisieri, Karoney, Mercy Jelagat, Cheruiyot, Priscilla Chepkorir, Cherutich, Salinah, Njuguna, Simon Wachira, Kirui, Viola Cherotich, Borok, Margaret, Chidziva, Ennie, Musoro, Godfrey, Hakim, James, Bhiri, Joyline, Phiri, Misheck, Mudzingwa, Shepherd, Manyanga, Tadios, Kiragga, Agnes, Banegura, Anchilla Mary, Hoppe, Anne, Balyegisawa, Apolo, Agwang, Betty, Isaaya, Brian, Tumwine, Constantine, Odongpiny, Eva Laker A., Asienzo, Jesca, Musaazi, Joseph, Paton, Nicholas, Senkungu, Peter, Walimbwa, Stephen, Kamara, Yvonne, Amperiize, Mathius, Allen, Elizabeth, Opondo, Charles, Mohammed, Perry, van Rein-van der Horst, Willemijn, Van Delft, Yvon, Boateng, Fafa Addo, Namara, Doreen, Kaleebu, Pontiano, Ojoo, Sylvia, Bwakura, Tapiwanashe, Katana, Milly, Venter, Francois, Phiri, Sam, Walker, Sarah

Source: The Lancet HIV; 20220101, Issue: Preprints